Pelthos Therapeutics PTHS
NYSE PTHS
$20.77 +0.11 (+0.53%)
At close: Oct 2, 2026 · 4:00 PM EDT

Pelthos Therapeutics (PTHS) Return on Sales [ROS] (2025 - 2026)

Updated

Pelthos Therapeutics (PTHS) recorded Return on Sales [ROS] of -111.02% in Q2 2026, up 8.98 percentage points from the prior quarter.

Analysis

Pelthos Therapeutics (PTHS) Return on Sales [ROS] (2025 - 2026) Analysis & Trends

On a TTM basis, Pelthos Therapeutics' Return on Sales [ROS] came in at -133.42% as of Jun 30, 2026; for FY2025, it came in at -193.09%.

  • Per Business Quant, the preceding three quarters came in at -120.01% (Q1 2026), -127.84% (Q4 2025) and -207.43% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Pelthos Therapeutics 77.24 Mn -11.16 Mn 11.99 Mn -111.02%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -111.02%
Mar 31, 2026 -120.01%
Dec 31, 2025 -127.84%
Sep 30, 2025 -207.43%
API Access

Pelthos Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=PTHS&period=max&api_key=YOUR_API_KEY